4/06/2021
The 20(+1) under 40: Inside the next generation of biotech leaders
Dr. Juliette Hordeaux, Senior Research Director at GTP is featured in Endpoints News’ annual “Under 40: Inside the next generation of biotech leaders.”
Catalyzing the development of gene therapeutics from concept to clinic
The Gene Therapy Program is a complex R&D organization with the internal capacity to perform gene transfer studies from basic research through phase 1/2 proof-of-concept human trials.
Providing investigators access to state-of-the-art vector technology
The Vector Core is a full service core facility with over a decade of experience in the production of viral-based vectors.
Partnering with industry leaders to advance the field of genetic therapeutics
The Gene Therapy Program aims to discover transformative genetic-based therapeutics, which are translated to proof-of-concept in clinical trials and commercialized through partnerships to assure access to patients in need.
Leading the field in AAV vector innovation
Next Generation AAV Vectors
This program represents our ambitious commitment to developing cutting-edge vector technologies. Our diversified approach focuses on delivering advanced vectors for traditional gene therapy applications as well as vectors tailored specifically for genome editing. The design of these transformative next-generation AAV vectors is being guided by experimental results from studies on the basic biology of AAV that leverage our world-class resources in molecular, structural, cell, and computational biology.
Spinal Muscular Atrophy (SMA)
A rare neuromuscular disorder
Spinal muscular atrophy (SMA) is a rare genetic disorder caused by mutations in the SMN1 gene. These mutations lead to a deficiency of the survival motor neuron (SMN) protein, which results in the loss of specialized nerve cells in the spinal cord and brainstem such that information cannot be passed from the brain to the muscle. This leads to severe muscle weakness and loss of muscle control, as well as impaired breathing and swallowing in severe cases. As part of a collaborative alliance with Biogen, GTP is developing an AAV gene therapy approach to elicit long-term expression of SMN1 in motor neurons for the treatment of SMA.
Crigler-Najjar Syndrome
A rare, congenital autosomal recessive monogenic disease
Crigler-Najjar Syndrome (CN) is a rare genetic disorder caused by a defect of the UGT1A1 gene, which encodes the protein responsible for metabolizing bilirubin. The resulting toxic accumulation of bilirubin can cause severe neurological impairment and death. Phototherapy can help manage bilirubin levels, but requires 10-12 hour treatments each day and becomes less effective with age, at which point a liver transplant is required. GTP and Audentes Therapeutics are collaborating to advance AAV8-UGT1A1 (AT342) for the treatment of CN. A phase 1/2, multinational, open-label, ascending-dose, delayed-treatment concurrent control clinical study is planned (VALENS; NCT03223194).